1	Management	Management	B-NP	NN	O	10	NMOD	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	early	early	B-NP	JJ	O	7	NMOD	0
4	and	and	I-NP	CC	O	7	NMOD	0
5	advanced	advanced	I-NP	JJ	O	7	NMOD	0
6	colorectal	colorectal	I-NP	JJ	O	7	NMOD	0
7	cancer	cancer	I-NP	NN	O	2	PMOD	0
8	:	:	O	:	O	1	P	0
9	therapeutic	therapeutic	B-NP	JJ	O	10	NMOD	0
10	issues	issue	I-NP	NNS	O	0	ROOT	0
11	.	.	O	.	O	10	P	0

1	PURPOSE	PURPOSE	B-NP	NN	O	4	NMOD	0
2	:	:	O	:	O	1	P	0
3	The	The	B-NP	DT	O	4	NMOD	0
4	staging	staging	I-NP	NN	O	10	NMOD	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	colorectal	colorectal	B-NP	JJ	O	7	NMOD	0
7	cancer	cancer	I-NP	NN	O	5	PMOD	0
8	,	,	O	,	O	10	P	0
9	therapeutic	therapeutic	B-NP	JJ	O	10	NMOD	0
10	decision	decision	I-NP	NN	O	23	NMOD	0
11	making	make	B-VP	VBG	O	10	NMOD	0
12	in	in	B-PP	IN	O	11	VMOD	0
13	the	the	B-NP	DT	O	14	NMOD	0
14	management	management	I-NP	NN	O	12	PMOD	16	management
15	of	of	B-PP	IN	O	14	NMOD	0
16	early	early	B-NP	JJ	O	20	NMOD	0
17	and	and	I-NP	CC	O	20	NMOD	0
18	advanced	advanced	I-NP	JJ	O	20	NMOD	0
19	colorectal	colorectal	I-NP	JJ	O	20	NMOD	0
20	cancer	cancer	I-NP	NN	O	15	PMOD	0
21	,	,	O	,	O	23	P	0
22	and	and	O	CC	O	23	NMOD	0
23	dilemmas	dilemma	B-NP	NNS	O	28	SUB	0
24	posed	pose	B-VP	VBN	O	23	NMOD	0
25	by	by	B-PP	IN	O	24	VMOD	0
26	drug-related	drug-related	B-NP	JJ	O	27	NMOD	0
27	toxicity	toxicity	I-NP	NN	O	25	PMOD	0
28	are	be	B-VP	VBP	O	0	ROOT	0
29	discussed	discuss	I-VP	VBN	O	28	VC	0
30	.	.	O	.	O	28	P	0

1	SUMMARY	SUMMARY	B-NP	NN	O	3	NMOD	0
2	:	:	O	:	O	1	P	0
3	Staging	Staging	B-NP	NN	O	7	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	colorectal	colorectal	B-NP	JJ	O	6	NMOD	0
6	cancer	cancer	I-NP	NN	O	4	PMOD	0
7	occurs	occur	B-VP	VBZ	O	0	ROOT	0
8	after	after	B-PP	IN	O	7	VMOD	0
9	surgery	surgery	B-NP	NN	O	8	PMOD	0
10	and	and	O	CC	O	7	VMOD	0
11	is	be	B-VP	VBZ	O	7	VMOD	0
12	based	base	I-VP	VBN	O	11	VC	0
13	on	on	B-PP	IN	O	12	VMOD	0
14	the	the	B-NP	DT	O	15	NMOD	0
15	extent	extent	I-NP	NN	O	13	PMOD	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	disease	disease	B-NP	NN	O	18	NMOD	0
18	invasiveness	invasiveness	I-NP	NN	O	20	NMOD	0
19	and	and	I-NP	CC	O	20	NMOD	0
20	dissemination	dissemination	I-NP	NN	O	16	PMOD	0
21	.	.	O	.	O	7	P	0

1	Surgery	Surgery	B-NP	NNP	O	2	SUB	0
2	is	be	B-VP	VBZ	O	0	ROOT	0
3	the	the	B-NP	DT	O	5	NMOD	0
4	primary	primary	I-NP	JJ	O	5	NMOD	0
5	treatment	treatment	I-NP	NN	O	2	PRD	0
6	for	for	B-PP	IN	O	5	NMOD	0
7	stage	stage	B-NP	NN	O	9	NMOD	0
8	I	I	I-NP	CD	O	9	NMOD	0
9	disease	disease	I-NP	NN	O	6	PMOD	0
10	.	.	O	.	O	2	P	0

1	Adjuvant	Adjuvant	B-NP	JJ	O	2	NMOD	0
2	chemotherapy	chemotherapy	I-NP	NN	O	3	SUB	19	chemotherapy
3	is	be	B-VP	VBZ	O	0	ROOT	0
4	recommended	recommend	I-VP	VBN	O	3	VC	0
5	after	after	B-PP	IN	O	4	VMOD	0
6	resection	resection	B-NP	NN	O	5	PMOD	0
7	in	in	B-PP	IN	O	6	NMOD	0
8	selected	select	B-NP	VBN	O	10	NMOD	0
9	high-risk	high-risk	I-NP	JJ	O	10	NMOD	0
10	patients	patient	I-NP	NNS	O	7	PMOD	0
11	with	with	B-PP	IN	O	10	NMOD	0
12	stage	stage	B-NP	NN	O	14	NMOD	0
13	II	II	I-NP	CD	O	14	NMOD	0
14	disease	disease	I-NP	NN	O	11	PMOD	0
15	and	and	B-PP	CC	O	5	PMOD	0
16	in	in	B-PP	IN	O	5	PMOD	0
17	all	all	B-NP	DT	O	18	NMOD	0
18	patients	patient	I-NP	NNS	O	16	PMOD	0
19	with	with	B-PP	IN	O	18	NMOD	0
20	stage	stage	B-NP	NN	O	22	NMOD	0
21	III	III	I-NP	CD	O	22	NMOD	0
22	disease	disease	I-NP	NN	O	19	PMOD	0
23	.	.	O	.	O	3	P	0

1	Convenience	Convenience	B-NP	NN	O	13	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	administration	administration	B-NP	NN	O	9	NMOD	0
4	,	,	O	,	O	9	P	0
5	tolerability	tolerability	B-NP	NN	O	9	NMOD	0
6	,	,	O	,	O	9	P	0
7	and	and	O	CC	O	9	NMOD	0
8	patient	patient	B-NP	NN	O	9	NMOD	0
9	factors	factor	I-NP	NNS	O	2	PMOD	0
10	not	not	O	RB	O	13	VMOD	0
11	necessarily	necessarily	B-ADVP	RB	O	13	VMOD	0
12	age	age	B-NP	NN	O	13	SUB	0
13	may	may	B-VP	MD	O	0	ROOT	0
14	be	be	I-VP	VB	O	13	VC	0
15	considerations	consideration	B-NP	NNS	O	14	PRD	0
16	in	in	B-PP	IN	O	15	NMOD	0
17	decisions	decision	B-NP	NNS	O	16	PMOD	0
18	about	about	B-PP	IN	O	14	VMOD	0
19	adjuvant	adjuvant	B-NP	JJ	O	20	NMOD	0
20	therapy	therapy	I-NP	NN	O	18	PMOD	0
21	after	after	B-PP	IN	O	20	NMOD	0
22	resection	resection	B-NP	NN	O	21	PMOD	0
23	.	.	O	.	O	13	P	0

1	Treatment	Treatment	B-NP	NN	O	7	SUB	19	Treatment
2	of	of	B-PP	IN	O	1	NMOD	0
3	stage	stage	B-NP	NN	O	6	NMOD	0
4	IV	IV	I-NP	CD	O	6	NMOD	0
5	colorectal	colorectal	I-NP	JJ	O	6	NMOD	0
6	cancer	cancer	I-NP	NN	O	2	PMOD	0
7	is	be	B-VP	VBZ	O	0	ROOT	0
8	based	base	I-VP	VBN	O	7	VC	0
9	on	on	B-PP	IN	O	8	VMOD	0
10	the	the	B-NP	DT	O	11	NMOD	0
11	type	type	I-NP	NN	O	9	PMOD	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	prior	prior	B-NP	JJ	O	14	NMOD	0
14	therapy	therapy	I-NP	NN	O	17	NMOD	0
15	and	and	O	CC	O	17	NMOD	0
16	patient-specific	patient-specific	B-NP	JJ	B-protein	17	NMOD	0
17	factors	factor	I-NP	NNS	I-protein	12	PMOD	0
18	.	.	O	.	O	7	P	0

1	Recently	Recently	B-ADVP	RB	O	7	VMOD	0
2	,	,	O	,	O	7	P	0
3	significant	significant	B-NP	JJ	O	4	NMOD	0
4	improvements	improvement	I-NP	NNS	O	7	SUB	0
5	in	in	B-PP	IN	O	4	NMOD	0
6	survival	survival	B-NP	NN	O	5	PMOD	0
7	have	have	B-VP	VBP	O	0	ROOT	0
8	been	be	I-VP	VBN	O	7	VC	0
9	achieved	achieve	I-VP	VBN	O	8	VC	0
10	through	through	B-PP	IN	O	9	VMOD	0
11	the	the	B-NP	DT	O	12	NMOD	0
12	use	use	I-NP	NN	O	10	PMOD	0
13	of	of	B-PP	IN	O	12	NMOD	0
14	combination	combination	B-NP	NN	O	15	NMOD	0
15	chemotherapy	chemotherapy	I-NP	NN	O	19	NMOD	0
16	and	and	O	CC	O	19	NMOD	0
17	monoclonal	monoclonal	B-NP	JJ	O	19	NMOD	0
18	antibody	antibody	I-NP	NN	O	19	NMOD	0
19	regimens	regimen	I-NP	NNS	O	13	PMOD	0
20	.	.	O	.	O	7	P	0

1	Bevacizumab	Bevacizumab	B-NP	NN	O	6	SUB	0
2	in	in	B-PP	IN	O	1	NMOD	0
3	combination	combination	B-NP	NN	O	2	PMOD	0
4	with	with	B-PP	IN	O	3	NMOD	0
5	chemotherapy	chemotherapy	B-NP	NN	O	4	PMOD	19	chemotherapy
6	is	be	B-VP	VBZ	O	0	ROOT	0
7	first-line	first-line	B-NP	JJ	O	8	NMOD	0
8	therapy	therapy	I-NP	NN	O	6	PRD	0
9	for	for	B-PP	IN	O	8	NMOD	0
10	stage	stage	B-NP	NN	O	12	NMOD	0
11	IV	IV	I-NP	CD	O	12	NMOD	0
12	disease	disease	I-NP	NN	O	9	PMOD	0
13	.	.	O	.	O	6	P	0

1	Age	Age	B-NP	NN	O	3	SUB	0
2	alone	alone	B-ADVP	RB	O	1	NMOD	0
3	should	should	B-VP	MD	O	0	ROOT	0
4	not	not	I-VP	RB	O	3	VMOD	0
5	preclude	preclude	I-VP	VB	O	3	VC	0
6	the	the	B-NP	DT	O	7	NMOD	0
7	use	use	I-NP	NN	O	5	OBJ	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	chemotherapy	chemotherapy	B-NP	NN	O	8	PMOD	19	chemotherapy
10	in	in	B-PP	IN	O	7	NMOD	0
11	stage	stage	B-NP	NN	O	14	NMOD	0
12	IV	IV	I-NP	CD	O	14	NMOD	0
13	colorectal	colorectal	I-NP	JJ	O	14	NMOD	0
14	cancer	cancer	I-NP	NN	O	10	PMOD	0
15	,	,	O	,	O	3	P	0
16	although	although	B-SBAR	IN	O	3	VMOD	0
17	the	the	B-NP	DT	O	18	NMOD	0
18	ability	ability	I-NP	NN	O	23	SUB	0
19	to	to	B-VP	TO	O	20	VMOD	0
20	tolerate	tolerate	I-VP	VB	O	18	NMOD	0
21	drug-related	drug-related	B-NP	JJ	O	22	NMOD	0
22	toxicity	toxicity	I-NP	NN	O	20	OBJ	0
23	may	may	B-VP	MD	O	16	SBAR	0
24	be	be	I-VP	VB	O	23	VC	0
25	a	a	B-NP	DT	O	26	NMOD	0
26	consideration	consideration	I-NP	NN	O	24	PRD	0
27	.	.	O	.	O	3	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	optimal	optimal	I-NP	JJ	O	3	NMOD	0
3	duration	duration	I-NP	NN	O	14	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	chemotherapy	chemotherapy	B-NP	NN	O	4	PMOD	19	chemotherapy
6	in	in	B-PP	IN	O	3	NMOD	0
7	patients	patient	B-NP	NNS	O	6	PMOD	0
8	with	with	B-PP	IN	O	7	NMOD	0
9	early	early	B-NP	JJ	O	13	NMOD	0
10	and	and	I-NP	CC	O	13	NMOD	0
11	metastatic	metastatic	I-NP	JJ	O	13	NMOD	0
12	colorectal	colorectal	I-NP	JJ	O	13	NMOD	0
13	cancer	cancer	I-NP	NN	O	8	PMOD	0
14	is	be	B-VP	VBZ	O	0	ROOT	0
15	unclear	unclear	B-ADJP	JJ	O	14	PRD	0
16	.	.	O	.	O	14	P	0

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	The	The	B-NP	DT	O	5	NMOD	0
4	optimal	optimal	I-NP	JJ	O	5	NMOD	0
5	approach	approach	I-NP	NN	O	12	SUB	0
6	to	to	B-PP	TO	O	5	NMOD	0
7	the	the	B-NP	DT	O	8	NMOD	0
8	treatment	treatment	I-NP	NN	O	6	PMOD	19	treatment
9	of	of	B-PP	IN	O	8	NMOD	0
10	colorectal	colorectal	B-NP	JJ	O	11	NMOD	0
11	cancer	cancer	I-NP	NN	O	9	PMOD	0
12	depends	depend	B-VP	VBZ	O	1	NMOD	0
13	on	on	B-PP	IN	O	12	VMOD	0
14	several	several	B-NP	JJ	O	15	NMOD	0
15	considerations	consideration	I-NP	NNS	O	13	PMOD	0
16	,	,	O	,	O	15	P	0
17	including	include	B-PP	VBG	O	15	NMOD	0
18	patient-specific	patient-specific	B-NP	JJ	B-protein	19	NMOD	0
19	factors	factor	I-NP	NNS	I-protein	17	PMOD	0
20	.	.	O	.	O	12	P	0

